Clinical trials: HES - Hypereosinophilic Syndrome
Asthma
Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
The purpose of the MEMORY trial is to compare the effects of mepolizumab with Placebo on airway physiology in patients with eosinophilic asthma
- Trial name
- MEMORY (NCT02594332)
- Testing
- Mepolizumab
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- Johannes Gutenberg University Mainz
Asthma; Eosinophilic
SIM0718 Treatment of Asthma Clinical Study
Phase III clinical study of SIM0718 asthma
- Trial name
- NCT06488755
- Testing
- SIM0718 injection
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Simcere Pharmaceutical Co., Ltd
Asthma, Asthma; Eosinophilic
Asthma Control in a Dutch Primary Care Population
Rationale: Despite the availability of effective treatment to reach symptom control, nearly half of the asthma patients remain inadequately controlled.
- Conditions
- Asthma, Asthma; Eosinophilic, Asthma Chronic, Asthma; Status
- Trial name
- NCT04456270
- Where
- Netherlands
- Volunteers
- 222 people
- Sponsor
- General Practitioners Research Institute
Asthma
A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.
- Trial name
- NCT05528679
- Testing
- 610 100mg, 610 300mg
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Hypereosinophilic Syndrome
A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
This is an open-label extension study to Study 200622.In this study subjects from Study 200622 will be continued on 4-weekly dosing with open-label mepolizumab 300 milligram (mg) subcutaneously (SC) for an additional 20 Weeks…
- Trial name
- NCT03306043
- Testing
- Mepolizumab
- Where
- 36 sites in United States, Argentina and 11 more
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
Severe Eosinophilic Asthma
A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
- Trial name
- ATHENA (NCT07214753)
- Testing
- benralizumab
- Where
- 28 sites in Italy
- Volunteers
- 335 people
- Sponsor
- AstraZeneca
Asthma
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Primary objective of the study is to evaluate whether patients with severe eosinophilic asthma who have received long-term treatment with mepolizumab (at least 3 years) need to maintain treatment with mepolizumab to continue to…
- Trial name
- NCT02555371
- Testing
- Mepolizumab 100mg
- Where
- 73 sites in United States, Argentina and 12 more
- Volunteers
- 306 people
- Sponsor
- GlaxoSmithKline
Asthma; Eosinophilic, Severe Asthma
Predictive Signature of Benralizumab Response
The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic…
- Trial name
- BENRAPRED (NCT04565483)
- Testing
- Benralizumab Prefilled Syringe
- Where
- 20 sites in France
- Volunteers
- 220 people
- Sponsor
- Nantes University Hospital
Respiratory System Agents, Anti-Asthmatic Agents
Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome
Background: Eosinophils are white blood cells that help fight infections. High eosinophil levels can damage people s organs, causing hypereosinophilic syndrome (HES).
- Conditions
- Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders
- Trial name
- HESIL5R (NCT02130882)
- Testing
- benralizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Bronchial Asthma, Eosinophilic Asthma
XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma
A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed…
- Trial name
- NCT04674137
- Testing
- XC8 100 mg
- Where
- 18 sites in Russia
- Volunteers
- 70 people
- Sponsor
- Chemlmmune Therapeutics LLC
Asthma; Eosinophilic
Homeostatic Roles of Eosinophils in Asthma
The HOMEOS study is an exploratory, observational, and monocentric research. It focuses on characterizing the homeostatic roles of eosinophils in severe asthma.
- Trial name
- HOMEOS (NCT06676397)
- Testing
- Blood Punction
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Eosinophilia, Hypereosinophilic Syndrome
Natural History of Hypereosinophilia and Hypereosinophilic Syndromes
Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.
- Trial name
- COHESION (NCT04018118)
- Testing
- Biological sample
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Lille
Hypereosinophilic Syndrome
Identification of New Markers in the Hypereosinophilic Syndrome
The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach.
- Trial name
- SHE (NCT01713504)
- Testing
- biologie sample
- Where
- France
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Severe Eosinophilic Asthma, Nasal Polyps
RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
The purpose of this observational study is to describe the population of patients with SEA + NP who have been prescribed FASENRA and assess available clinical outcomes for both NP and asthma.
- Trial name
- RANS (NCT05180357)
- Testing
- FASENRA(benralizumab)
- Where
- 45 sites in United States, France and 4 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Toxicity of anti-IL-5
- Conditions
- Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
- Trial name
- NCT00266565
- Testing
- Mepolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Asthma
A Study of Depemokimab in Participants of 6 to 11 Years of Age
This study is aimed at assessing depemokimab as an add-on medicine for the treatment of asthma with type-2 inflammation in participants of 6 to 11 years of age.
- Trial name
- GLIDE (NCT07671001)
- Testing
- Depemokimab
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Severe Eosinophilic Asthma
Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece
A prospective multi-centre, non-interventional observational study, that will be conducted in several centers in Greece for a 2-year time period (completion date December 2020), to describe patient characteristics, medical…
- Trial name
- NCT04084613
- Volunteers
- 150 people
- Sponsor
- Attikon Hospital
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00255346
- Testing
- Dasatinib (BMS-354825)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Asthma
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
This is a multi-centre, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of mepolizumab adjunctive therapy in participants with severe eosinophilic asthma on markers of asthma control.
- Trial name
- NCT02281318
- Testing
- Mepolizumab, SOC
- Where
- 144 sites in United States, Argentina and 17 more
- Volunteers
- 556 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.